This project is an FDA-approved clinical trial of a whole plant-derived, high-CBD sublingual tincture for the treatment of anxiety.

In collaboration with Dr. Brent Forester, we are investigating CBD as a potential treatment for anxiety and agitation that often appears in mild to moderate Alzheimer's Disease. Behavioral symptoms of Alzheimer's Disease, such as anxiety and agitation, often contribute to the caregiver stress associated with caring for a loved one with Alzheimer's. At the moment, there are no FDA-approved treatments for these symptoms, and the current treatment options can have significant negative side effects. This study seeks to discover a safe and effective treatment for anxiety and agitation in those living with Alzheimer's.

This study is an FDA-approved clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions.

This project is an FDA-approved clinical trial of a hemp-derived, high-CBD sublingual product for the treatment of anxiety and depression in individuals with bipolar disorder.

Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain, and sleep disturbance, all of which significantly impact their quality of life.

Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.

Despite recent increases in both medical and recreational cannabis in the United States and globally, little research has been conducted to determine the potential applications for womens health. Specifically, a variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, such as dysmennorhea, endometriosis, painful intercourse, and menopause-related symptoms.

This will be the first study to assess the impact of a local hemp-derived, full spectrum suppository high in cannabidiol (CBD) and cannabigerol (CBG) on pharmacokinetic/pharmacodynamic (PK/PD) variables and clinical symptoms in individuals with endometriosis.

Despite growing interest in medical cannabis, specifically CBD products, and their potential use for a wide variety of disorders, no studies to date have conducted in-depth examinations of the effects of cannabinoid treatment on both clinical state and cognition in veterans. This investigation will examine Veterans using various cannabinoid-based products, including high-CBD products.

This project is designed to understand the impact of "real-world' medical cannabis treatment on various outcome measures. It is a non-invasive observational, longitudinal study examining individuals who are considering medical cannabis, hemp or other cannabinoids (and those who are not) for various medical and/or psychological conditions.

More than half of older adults report bothersome pain within the past month. Further, opioid use for pain is highest among older adults, yet many complain of inadequate relief, significant side effects and increased risk of opioid-related consequences. Medical cannabis (MC) use is increasingly common among older adults for pain relief; however, the potential benefits, risks, and negative consequences of MC in this population have not been assessed.

This project is an FDA-approved clinical trial of a hemp-derived, high-CBD sublingual product for the treatment of anxiety.

This investigation is designed to clarify the impact of the use of FORIA Basics, a CBD-containing vaginal suppository, among women reporting active menstrual cycle-related symptomatology. Taking Foria is not a part of the study procedures, and you will not be required to use Foria to participate in the study.